 HOUSTON, April 15, 2021 PRNewswire -- Soliton, Inc., Nasdaq: SOLY Soliton or the Company, a medical device company with a novel and proprietary platform technology, today announced that the U.S. Food and Drug Administration FDA has accepted its special 510k application previously submitted on March 31, 2021 for modifications to RESONICTM device planned for commercial launch as complete. The company expects to hear if the FDA has cleared its special 510k application in the next 15-20 days unless the process takes slightly longer than normal given the COVID-related workload inside the FDA. 